Company Overview
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns for food producers and processors. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems used for administering antibiotics and vaccines under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin, used in dogs to assist in managing pyoderma; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis on the results from multiple locations over extended periods. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Why Investors Should Care
Revenue has grown at a 12.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.39.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- May 2026 Revenue of $870.40M (-2.7% YoY); net profit $-7.90M.
- Trailing 12 Months Year-on-year growth — revenue -0.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 12.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 12.07% |
| 1 Year: | -0.10% |
Stock Price Performance
| 1 Year: | +113.54% |
| 6 Months: | +21.96% |
| 3 Months: | +32.92% |
| 1 Month: | +4.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.27 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 12.1% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NEOG Neogen Corporation R2KR3KPHARMA | 11.83 | -295.75 | $2.58B | 0.00% | -0.68% | -0.38% | 12.07% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | May 2015 | Aug 2015 | Nov 2015 | Feb 2016 | May 2016 | Aug 2016 | Nov 2016 | Feb 2017 | May 2017 | Aug 2017 | Nov 2017 | Feb 2018 | May 2018 | Aug 2018 | Nov 2018 | Feb 2019 | May 2019 | Aug 2019 | Nov 2019 | Feb 2020 | May 2020 | Aug 2020 | Nov 2020 | Feb 2021 | May 2021 | Aug 2021 | Nov 2021 | Feb 2022 | Aug 2022 | Nov 2022 | Feb 2023 | Aug 2023 | Nov 2023 | Feb 2024 | Aug 2024 | Nov 2024 | Feb 2025 | Aug 2025 | Nov 2025 | Feb 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 94.21M | 100.70M | 94.90M | - | 99.63M | 107.10M | 97.70M | - | 101.42M | 107.80M | 99.87M | - | 109.33M | 115.00M | 116.71M | - | 128.31M | 130.52M | 128.24M | 132.35M | 230.03M | 218.25M | 228.99M | 229.63M | 228.81M | 216.96M | 231.26M | 221.00M | 209.19M | 224.69M | 211.20M |
| Gross Profit | 37.70M | 37.79M | 38.22M | 35.20M | 41.85M | 40.48M | 43.59M | 40.88M | 47.02M | 44.92M | 48.25M | 44.60M | 48.50M | 46.73M | 50.03M | 44.63M | 50.53M | 48.19M | 51.03M | 45.33M | 51.73M | 50.30M | 53.21M | 53.85M | 57.69M | 60.01M | 60.59M | 57.41M | 62.27M | 112.54M | 107.96M | 116.76M | 116.77M | 116.88M | 104.93M | 113.33M | 110.30M | 94.97M | 106.68M | 99.00M |
| Operating Income | - | 14.89M | 14.61M | 11.25M | - | 14.74M | 16.85M | 14.35M | - | 16.42M | 18.00M | 15.91M | - | 16.48M | 18.25M | 14.64M | - | 16.26M | 18.27M | 13.04M | - | 18.89M | 19.25M | 15.77M | - | 21.75M | 12.47M | 6.38M | 6.06M | -7.66M | 15.68M | 19.14M | 14.46M | 12.02M | 2.26M | -457.48M | 5.40M | -16.09M | -5.38M | -3.30M |
| Net Income | 9.43M | 9.29M | 9.14M | 8.29M | 9.82M | 9.88M | 11.15M | 10.29M | 12.47M | 11.91M | 17.10M | 16.59M | 17.55M | 15.24M | 16.05M | 13.07M | - | 14.65M | 16.28M | 12.20M | - | 15.86M | 15.88M | 13.38M | - | 17.08M | 10.83M | 5.44M | 5.21M | -41.84M | 8.19M | 1.50M | -3.49M | -2.02M | -12.61M | -456.28M | -10.90M | 36.34M | -15.92M | -17.00M |
| Diluted EPS | 0.25 | 0.25 | 0.24 | 0.22 | 0.26 | 0.20 | 0.22 | 0.20 | 0.24 | 0.23 | 0.33 | 0.32 | 0.33 | 0.29 | 0.31 | 0.25 | 0.30 | 0.14 | 0.15 | 0.11 | 0.15 | 0.15 | 0.15 | 0.12 | 0.15 | 0.16 | 0.10 | 0.05 | 0.05 | -0.19 | 0.04 | 0.01 | -0.02 | -0.01 | -0.06 | -2.10 | -0.05 | 0.17 | -0.07 | -0.08 |
| R&D Expense | - | 2.57M | 2.62M | 2.45M | - | 2.68M | 2.77M | 2.64M | - | 3.10M | 2.97M | 2.84M | - | 2.82M | 3.17M | 3.25M | - | 3.69M | 3.78M | 3.82M | - | 3.88M | 4.06M | 4.24M | - | 4.33M | 4.33M | 4.56M | 4.88M | 6.85M | 7.26M | 6.72M | 5.76M | 4.85M | 5.20M | 5.11M | 4.50M | 5.12M | 4.56M | 3.80M |
Profit & Loss (Annual)
Figures in USD.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 | May 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 140.51M | 172.68M | 184.05M | 207.53M | 247.41M | 283.07M | 321.27M | 358.28M | 397.93M | 414.19M | 418.17M | 468.46M | 527.16M | 822.45M | 924.22M | 894.66M | 870.40M |
| Gross Profit | 72.97M | 87.79M | 92.42M | 109.49M | 122.60M | 139.69M | 153.06M | 168.92M | 186.27M | 191.92M | 196.28M | 215.06M | 243.01M | 405.95M | 463.90M | 421.38M | 408.50M |
| Operating Income | 26.88M | 35.84M | 33.74M | 40.71M | 43.39M | 53.12M | 56.39M | 64.94M | 70.19M | 68.09M | 67.52M | 74.17M | 58.62M | 37.52M | 58.66M | -1.06B | -21.60M |
| Net Income | 17.52M | 22.84M | 22.51M | 27.19M | 28.16M | 33.53M | 36.56M | 43.79M | 63.15M | 60.18M | 59.48M | 60.88M | 48.31M | -22.87M | -9.42M | -1.09B | -7.90M |
| Diluted EPS | 0.76 | 0.96 | 0.62 | 0.75 | 0.76 | 0.90 | 0.72 | 0.86 | 1.21 | 0.57 | 0.56 | 0.57 | 0.45 | -0.12 | -0.04 | -5.03 | -0.04 |
| R&D Expense | 6.26M | 6.83M | 6.64M | 7.78M | 8.33M | 9.58M | 9.89M | 10.38M | 10.86M | 12.80M | 14.75M | 16.25M | 17.05M | 26.04M | 22.48M | 21.09M | 18.40M |
Balance Sheet (Annual)
Figures in USD.
| Metric | May 2009 | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 | May 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 180.23M | 219.66M | 251.60M | 290.56M | 345.30M | 392.18M | 449.94M | 528.41M | 618.01M | 695.74M | 797.18M | 920.19M | 992.93M | 4.55B | 4.55B | 3.44B | 3.35B |
| Total Equity | 128.68M | 153.22M | 188.65M | 218.84M | 258.22M | 306.36M | 350.97M | 404.20M | 471.61M | 560.17M | 637.90M | 725.18M | 840.38M | 887.37M | 3.13B | 3.14B | 2.07B | 2.09B |
| Cash & Equivalents | 13.84M | 22.81M | 35.84M | 49.05M | 50.03M | 40.67M | 66.06M | 55.26M | 77.57M | 83.07M | 41.69M | 66.27M | 75.60M | 44.47M | 163.24M | 170.61M | 129.00M | 185.50M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 885.44M | 888.39M | 874.81M | 793.70M |
| Total Liabilities | - | - | 30.68M | 32.55M | 32.27M | 39.00M | 41.22M | 45.78M | 56.65M | 57.83M | 57.84M | 72.00M | 79.81M | 105.56M | 1.42B | 1.40B | 1.37B | 1.25B |
| Current Liabilities | - | - | 17.80M | 19.98M | 17.72M | 24.97M | 25.46M | 28.60M | 36.00M | 38.69M | 38.25M | 48.49M | 53.60M | 77.84M | 145.47M | 154.32M | 174.01M | 158.20M |
Cash Flows (Annual)
Figures in USD.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 | May 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 27.99M | 28.84M | 22.28M | 26.56M | 21.67M | 35.33M | 60.27M | 69.13M | 63.84M | 85.88M | 81.09M | 68.04M | 41.03M | 35.26M | 58.24M | 83.20M |
| Investing Cash Flow | -25.73M | -28.04M | -15.79M | -37.95M | -51.29M | -61.15M | -62.14M | -83.08M | -119.15M | -88.78M | -105.56M | -97.23M | 201.04M | -29.31M | -99.19M | 70.50M |
| Financing Cash Flow | 6.71M | 12.03M | 6.88M | 12.49M | 19.61M | 15.31M | 25.07M | 22.84M | 13.90M | 29.41M | 33.54M | 6.81M | -118.08M | 1.92M | -1.60M | -99.40M |
| Capital Expenditure | - | - | -1.50M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | 20.78M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Share Buybacks | - | - | - | - | - | - | - | - | 3.13M | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 | May 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 51.9% | 50.8% | 50.2% | 52.8% | 49.6% | 49.3% | 47.6% | 47.1% | 46.8% | 46.3% | 46.9% | 45.9% | 46.1% | 49.4% | 50.2% | 47.1% | 46.9% |
| Operating Margin % | 19.1% | 20.8% | 18.3% | 19.6% | 17.5% | 18.8% | 17.6% | 18.1% | 17.6% | 16.4% | 16.1% | 15.8% | 11.1% | 4.6% | 6.3% | -118.6% | -2.5% |
| Net Margin % | 12.5% | 13.2% | 12.2% | 13.1% | 11.4% | 11.8% | 11.4% | 12.2% | 15.9% | 14.5% | 14.2% | 13.0% | 9.2% | -2.8% | -1.0% | -122.1% | -0.9% |
| ROE % | 11.4% | 12.1% | 10.3% | 10.5% | 9.2% | 9.6% | 9.0% | 9.3% | 11.3% | 9.4% | 8.2% | 7.2% | 5.4% | -0.7% | -0.3% | -52.7% | -0.4% |
| ROCE % | - | 17.8% | 14.6% | 14.9% | 13.5% | 14.5% | 13.4% | 13.2% | 12.1% | 10.4% | 9.0% | 8.6% | 6.4% | 0.9% | 1.3% | -32.4% | -0.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.33% | 33.43M | $389.81M |
| 2 | Neuberger Berman Group, LLC | 7.60% | 16.57M | $193.22M |
| 3 | Vanguard Portfolio Management LLC | 5.98% | 13.04M | $152.03M |
| 4 | Dimensional Fund Advisors LP | 4.51% | 9.83M | $114.60M |
| 5 | Vanguard Capital Management LLC | 4.43% | 9.66M | $112.58M |
| 6 | SG Americas Securities, LLC | 4.29% | 9.35M | $109.05M |
| 7 | T. Rowe Price Investment Management, Inc. | 4.28% | 9.33M | $108.83M |
| 8 | ING Groep N.V. | 4.17% | 9.10M | $106.13M |
| 9 | State Street Corporation | 4.10% | 8.95M | $104.31M |
| 10 | Gates Capital Management, Inc. | 4.01% | 8.74M | $101.93M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NEOG
Is Neogen (NEOG) Already Overvalued After A 106% Run? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQaUc3M2lxREpiV2w4azBtWG1qUEY4S3JDSDRxUDBTQnBodm1fLXhVZWo1OER1ZHBfTVYtXzJsM3NXQ1pWQUtpejZvRWFITkZuX01jSE1fX2lJZVN0Q3k3cS1saDlpbDlKWVR0bTI2VXh2OUkwZDc2Nkg5TnlxSWN5SnBEcGZrU3JHdDJtck…
Legal & General Group Plc Makes New Investment in Neogen Corporation $NEOG - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPRHpOb0hRdWdEb2JwNVhvbl90bjdmMVc2S1RrRnR2QWc3Ql9HMFJVMkhEbnFma2xUbG9MeDlRVS02V2pNZURZaGpmV0ZFTkF5RXdGODVjU3NXRnJJVWNfVFRWNU1XRjBDWGtBUldZTDRDNnBMb3hzN25SZC1GaDhmQzdER20yTkF6LXpJY0…
NEOGEN CORP ($NEOG) President & CEO 2026 Pay Revealed - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPOGVDb2JJZVF5RjZ4RnZrUVhGX3U1em5Odmdnc1ZqY0pYdFVNQ2JOMXdkY3FxcEQzSERCUGtJY1p4TkRESnlaODFJZjd4dFVBWVZYaVNaS1ZwajBucHNBMEdBTmRKRVpxQld4ZWFoOS1sR3RwQkZzbGxrX0xFdE4xemVWNk1mQk45ZFJUbm…
NEOG - Neogen Corp Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBrX3dUX3RDQUx2anM1MkVfM1pLRTM3RTV1dUM3akwwVVZmcmNweFBSRnpNemRWSW1Dd055ODl0X3dHVnVuWnc?oc=5" target="_blank">NEOG - Neogen Corp Stock Price and Quote</a> <font color="#6f…
Neogen stock upgraded at Piper Sandler (NEOG:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE0yYlhvYThvN20wVWhndDhucHdEME5kbVRNTjlrVW1QS016aDRaaWhpa0F2dGNGOEJtbVFvcFhEQkJVRDJWbXlBWU4xb1RYVmEyendJWE9tZURGR2M1UkxsWVQ4SGo3R1JpQ2ZkLUJnMlJUTDAzdWxjNTFoZ09Xdw?oc=5" target="_blan…
Avoiding Lag: Real-Time Signals in (NEOG) Movement - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQbDMxQ0VYdVVDUHZoQ1dJREF5V1hxM0lGdGYwX1lYYkVZd2R3R0xoQUVpTFVoa3VPNUJydTVjSHVFSldJbWt6RFNlbVdUU0JDWGFrWEMwb1RTaGUyaENpdkJJSG5tUGVVZE1mbUFXYnVmMjhlVXdvYUR1ZE1teWc4T1NYV0VJclZ4RVBNUU…
NEOG — Frequently Asked Questions
What is the current share price of Neogen Corporation (NEOG)?
As of 2026-09-07 16:24 PDT, Neogen Corporation (NEOG) trades at $11.83 on NasdaqGS. Its 52-week range is $5.27 to $12.15.
What is the market capitalisation of NEOG?
Neogen Corporation (NEOG) has a market capitalisation of $2.58B on NasdaqGS.
What is the P/E ratio of NEOG?
NEOG trades at a trailing price-to-earnings (P/E) ratio of -295.75. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.19.
What is the return on equity (ROE) of NEOG?
NEOG has a return on equity (ROE) of -0.38%. Its return on capital employed (ROCE) is -0.68%.
Is NEOG a good stock to buy?
This page provides a data-driven analysis of Neogen Corporation (NEOG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.